| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 1,412,284 | 1,315,300 | 1,117,279 | 1,001,599 |
| Cost of sales - product | - | - | 165,002 | 170,462 |
| Cost of sales - product-Product | 196,510 | 164,606 | - | - |
| Gross profit | 1,215,774 | 1,150,694 | 952,277 | 831,137 |
| Research and development | 523,662 | 524,896 | 481,887 | 496,179 |
| Selling, general and administrative | 528,998 | 537,913 | 459,288 | 455,223 |
| Total operating expenses | 1,052,660 | 1,062,809 | 941,175 | 951,402 |
| Income (loss) from operations | 163,114 | 87,885 | 11,102 | -120,265 |
| Interest income, net | 3,029 | 3,497 | 5,848 | 10,643 |
| Other (expense) income, net | -18,979 | 8,167 | 3,950 | 11,318 |
| Income (loss) before income taxes | 147,164 | 99,549 | 20,900 | -98,304 |
| Income tax expense | 22,323 | 5,229 | 19,630 | 23,046 |
| Net income (loss) | 124,841 | 94,320 | 1,270 | -121,350 |
| Basic (in dollars per share) | 0.09 | 0.07 | 0 | -0.09 |
| Diluted (in dollars per share) | 0.08 | 0.06 | 0 | -0.09 |
| Weighted-average shares outstanding diluted (in shares) | 1,488,750,354 | 1,463,277,401 | 1,445,253,219 | 1,376,751,873 |
| Weighted-average shares outstandingbasic (in shares) | 1,432,801,699 | 1,408,166,754 | 1,390,052,966 | 1,376,751,873 |
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)